RxDoctor Payments Data

Danielle Fowler, NP

Nurse Practitioner · Nampa, IDNPI 1053007831

Payments from drug & device makers

$1,683in general payments, 2019–2025

Across 52 payments — averaging $32.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$542
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$217
  • Novo Nordisk$202
  • E.r. Squibb & Sons, L.L.C.$187
  • Novartis$145
  • Actelion Pharmaceuticals US, Inc.$144
  • plus $247 from 6 others

What the payments were for

  • Food & beverage$1,683100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,683 in reported general payments places this provider in the 85th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$4,854
Medicare patients
46
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$209,735
FarxigaDapagliflozin Propanediol172$148,587
EntrestoSacubitril/Valsartan69$86,947
Repatha SureclickEvolocumab62$59,362
XareltoRivaroxaban30$38,341
JardianceEmpagliflozin25$26,333
OzempicSemaglutide19$17,738
Praluent PenAlirocumab18$12,822
Metoprolol Succinate430$4,343
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$2,865
Candesartan Cilexetil57$2,749
Atorvastatin Calcium242$1,996
Rosuvastatin Calcium116$1,672
Isosorbide Mononitrate ErIsosorbide Mononitrate79$1,327
ClopidogrelClopidogrel Bisulfate118$1,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$542$148,587172 claims
NovartisEntresto$145$86,94769 claims
Boehringer IngelheimJardiance$20$26,33325 claims
Novo NordiskOzempic$202$17,73819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →